NEW YORK--(BUSINESS WIRE)--Piper Jaffray Companies (NYSE: PJC), a leading investment bank and asset management firm, is pleased to announce the hiring of Danielle Brill and Joe Catanzaro as senior research analysts in its healthcare equity research group. Covering the biotech sector, Brill and Catanzaro will be based in the firm’s New York office.
“Biopharma is core to our strategy at Piper Jaffray and these hires demonstrate our commitment to providing our institutional and corporate clients with the highest-quality equity research in the industry,” said Michael Cox, co-head of global equities at Piper Jaffray. “When combined with recent additions in sales and trading, we now have one of the broadest biopharma equities platforms on Wall Street.”
Brill has more than 10 years’ experience in the pharmaceutical industry. Prior to joining Piper Jaffray, Brill was an analyst with Needham & Company covering smid-cap biotech companies. Brill also worked as a clinical pharmacist at Mount Sinai Hospital and Premier Inc., and as a senior research technician at New York University and Columbia University Medical Center. She received a bachelor’s degree in biology from Michigan State University and earned a doctorate of pharmacy from Ernest Mario School of Pharmacy at Rutgers University.
Prior to joining Piper Jaffray, Catanzaro was a biotech equity research associate at Cowen Inc., where he led the production of Cowen’s biannual Investor’s Guide to Immuno-Oncology. Prior to Cowen Inc., Catanzaro served as a graduate research assistant at Stony Brook University School of Medicine and authored several publications in peer-reviewed journals. Catanzaro received a bachelor’s degree in biology from Binghamton University and earned a doctorate in genetics from Stony Brook University School of Medicine.
Piper Jaffray Companies (NYSE: PJC) is a leading investment bank and asset management firm. Securities brokerage and investment banking services are offered in the U.S. through Piper Jaffray & Co., member SIPC and FINRA; in Europe through Piper Jaffray Ltd., authorized and regulated by the U.K. Financial Conduct Authority; and in Hong Kong through Piper Jaffray Hong Kong Limited, authorized and regulated by the Securities and Futures Commission. Asset management products and services are offered through five separate investment advisory affiliates―U.S. Securities and Exchange Commission (SEC) registered Advisory Research, Inc., Piper Jaffray Investment Management LLC, PJC Capital Partners LLC and Piper Jaffray & Co., and Guernsey-based Parallel General Partners Limited, authorized and regulated by the Guernsey Financial Services Commission.
© 2018 Piper Jaffray Companies. 800 Nicollet Mall, Suite 1000, Minneapolis, Minnesota 55402-7036